Новые возможности применения агонистов I1-имидазолиновых рецепторов в практике семейного врача

Владимир Иванович Кузнецов; Богдан Богданович Радыш; Елена Александровна Басова; Инесса Степановна Каткова; Сергей Левонович Сафарян

Новые возможности применения агонистов I1-имидазолиновых рецепторов в практике семейного врача

Владимир Иванович Кузнецов¹, Богдан Богданович Радыш², Елена Александровна Басова³, Инесса Степановна Каткова⁴, Сергей Левонович Сафарян⁵

научная статья Страницы: 23-28

¹ д.м.н., профессор, засл. врач РФ, кафедра общей врачебной практики, Медицинский институт ФПКМР, Российский университет дружбы народов (Москва)
² д.м.н., зав. кафедрой геронтологии, Медицинский институт, Российский университет дружбы народов (Москва)
³ ординатор, кафедра общей врачебной практики, Российский университет дружбы народов (Москва)
⁴ к.м.н., зам. гл. врача по экспертизе временной нетрудоспособности, врач функциональной диагностики, ГП №25 ДЗМ (Москва)
⁵ гл. врач, КДП № 121 ДЗМ (Москва)

Ключевые слова: имидазолиновые рецепторы моксонидин рилменидин рефрактерная артериальная гипертензия сахарный диабет метаболический синдром

Аннотация

Представлены клинические аспекты применения в практике врача агонистов I1-имидазолиновых рецепторов, обладающих выраженным длительным гипотензивным действием, положительными метаболическими эффектами и минимальным побочным действием по сравнению с другими центральными адреномиметиками.

Для цитирования

Кузнецов В.И., Радыш Б.Б., Басова Е.А., Каткова И.С., Сафарян С.Л. Новые возможности применения агонистов I1-имидазолиновых рецепторов в практике семейного врача // Технологии живых систем. 2015. № 3. С. 23–28.

Список источников

Edwards L.P., Brown-Bryan T.A., McLean L., Ernsberger P.Pharmacological properties of the central antihypertensive agent, moxonidine // Cardiovasc Ther.2012. V.30(4). P.199-208.
Sanjuliani A.F., Francischetti E.A., Genethu de Abreu V., et at.Effects of moxonidine on the sympathetic nervous system, blood pressure, plasma renin activity, plasma atdosterone, leptin, and metabolic profile in obese hypertensive patients // Journal of Clinical and Basic Cardiotogy. 2004. Is. 1-4.P.19-25.
Mukaddam-Daher S.,Gutkowska J. Imidazoline receptors in the heart: a novel target and a novel mechanism of action that involves atrial natriuretic peptides // Braz. J. Med. Biol. Res.2004. V.37(8). P.1239-1245.
Prichard B.N., Owens C.W.,Graham B.R. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent // J. Hum. Hypertens.1997. V.11. Suppl. 1. P.S29-45.
Doggrell S.A. Moxonidine: some controversy // Expert Opin Pharmacother.2001. V.2(2). P.337-350.
Gaponova N.I.,Abdrakhmanov V.R.,Baratashvili V.L.,Tereshchenko S.N.Analysis of efficacy and safety of administration ofmoxonidinein patients with arterial hypertension and hypertensive crises // Kardiologiia.2011. V.51(6). P.91-96.
Sica D.A. Centrally acting anti-hypertensive agents: an update // J. Clin. Hypertens (Greenwich).2007. V.9(5). P.399-405.
Giannopoulos G.,Kossyvakis C.,Efremidis M., et al.Central Sympathetic Inhibition to Reduce Post-Ablation Atrial Fibrillation Recurrences in Hypertensive Patients: A Randomized Controlled Study // Circulation.2014. V.21. P.123-129.
Hetterich N.,Lauterbach E.,Stürer A.,Weilemann L.S.,Lauterbach M. Toxicity of antihypertensives in unintentional poisoning of young children // J. Emerg. Med.2014. V.47(2). P.155-162.
Kujala S.M.,Pöyhönen-Alho M,Kaaja R.J. Effects of sympatholytic therapy on postmenopausal symptoms in hypertensive postmenopausal women // Climacteric.2014. V.17(4). P.356-362.
Krespi P.G., Makris T.K., Hatzizaxarias A.N., Triposkiadis P., Tsoukala C., Kyriaki D., et al.Moxonidine effect on microalbuminuria, thrombomodulin, and plasminogen activator inhibitor-1 levels in patients with essential hypertension// Cardiovasc Drugs Ther. 1998. V.12. P. 463-467.
Ruksin V.V.,Grishin O.V.,Chiritso M.M. The efficacy of antihypertension drugs and their combinations in the non-treated hypertension// Med. Tr. Prom. Ekol.2013. № 5. P.7-11.
Chazova I.E., Almazov V.A., Shlyakhto E.V. Moxonidine improves glycaemic control in mildy hypertensive, overweight patients: a comparison with metformin // Diabetes, Obesity and Metabolism. 2006. V.8. P.456-465.
Chazova I, Schlaich M.P. Improved hypertension control with the imidazoline agonist moxonidine in a multinational metabolic syndrome population: principal results of the MERSY Study // International J. Hypertension. 2013. № 1. P. 1-9.
Sharma A.M., et al.Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study// J. Hum. Hypertens. 2004. V. 18. P. 669-675.
Holecki M., Dulawa J., Chulek J. Resistant hypertension in visceral obesity// Eur. J. Intern. Med. 2012. V. 23. P. 643-648.
Bramalage P., Pittrow D., Witchen H.U.,et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly contolled // Am. J. Hyperens. 2004. V.17. P. 904-910.
Jordan J., Yumuk V., Schlaich M., et al. Joint statement of the European Association for the study of the study of obesity and the European Society of Hypertension obesity and difficult to treat arerial hypertension // J. hypertens. 2012. V. 30 P. 1047-1055.
Engbaek M., Hjerrild M., Hallas J., Jacobsen I.A. The effect of low-dose spironolactone on resistant hypertension // J. Am. Soc. hypertens. 2010. V.4. P.290-294.
Tsioufis C., Kordalis A., Flessas D. et al. Pathophysiology of resistant hypertension: the role of sympathic nervous system // Int. J. Hypertens. 2011. № 2. P. 34-41.
SagaradS.V., Biradar-Kerure S., Ramakrishna M.R., Chaitanya K.S, Reddy S.S. A Prospective Real World Experience of Moxonidine Use in Indian Hypertensive Patients-Prescription beyond Current Guidelines// J. Clin. Diagn. Res. 2013. V. 7(10). P. 2213-2215.
Bousquet P., Feldman. J, Schwartz J. Central cardiovascular effects of alpha-adrenergic drugs: difference between catecholamines and Imidazolines // J. Pharmacol. Exp. Ther. 1984. V. 230. P.232-236.
Подзолков В.И., Можарова Л.Г., Хомицкая Ю.В.Применение моксонидина для коррекции артериальной гипертонии у женщин с климактерическим синдромом // Кардиоваскулярная терапия и профилактика. 2005. №5. C. 83-88.
Cohn J.N., Pfeffer M.A., Rouleauc J., et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON) // Eur. J. Heart Fail. 2003. № 5. P. 659-667.

[1] Edwards L.P., Brown-Bryan T.A., McLean L., Ernsberger P.Pharmacological properties of the central antihypertensive agent, moxonidine // Cardiovasc Ther.2012. V.30(4). P.199-208.

[2] Sanjuliani A.F., Francischetti E.A., Genethu de Abreu V., et at.Effects of moxonidine on the sympathetic nervous system, blood pressure, plasma renin activity, plasma atdosterone, leptin, and metabolic profile in obese hypertensive patients // Journal of Clinical and Basic Cardiotogy. 2004. Is. 1-4.P.19-25.

[3] Mukaddam-Daher S.,Gutkowska J. Imidazoline receptors in the heart: a novel target and a novel mechanism of action that involves atrial natriuretic peptides // Braz. J. Med. Biol. Res.2004. V.37(8). P.1239-1245.

[4] Prichard B.N., Owens C.W.,Graham B.R. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent // J. Hum. Hypertens.1997. V.11. Suppl. 1. P.S29-45.

[5] Doggrell S.A. Moxonidine: some controversy // Expert Opin Pharmacother.2001. V.2(2). P.337-350.

[6] Gaponova N.I.,Abdrakhmanov V.R.,Baratashvili V.L.,Tereshchenko S.N.Analysis of efficacy and safety of administration ofmoxonidinein patients with arterial hypertension and hypertensive crises // Kardiologiia.2011. V.51(6). P.91-96.

[7] Sica D.A. Centrally acting anti-hypertensive agents: an update // J. Clin. Hypertens (Greenwich).2007. V.9(5). P.399-405.

[8] Giannopoulos G.,Kossyvakis C.,Efremidis M., et al.Central Sympathetic Inhibition to Reduce Post-Ablation Atrial Fibrillation Recurrences in Hypertensive Patients: A Randomized Controlled Study // Circulation.2014. V.21. P.123-129.

[9] Hetterich N.,Lauterbach E.,Stürer A.,Weilemann L.S.,Lauterbach M. Toxicity of antihypertensives in unintentional poisoning of young children // J. Emerg. Med.2014. V.47(2). P.155-162.

[10] Kujala S.M.,Pöyhönen-Alho M,Kaaja R.J. Effects of sympatholytic therapy on postmenopausal symptoms in hypertensive postmenopausal women // Climacteric.2014. V.17(4). P.356-362.

[11] Krespi P.G., Makris T.K., Hatzizaxarias A.N., Triposkiadis P., Tsoukala C., Kyriaki D., et al.Moxonidine effect on microalbuminuria, thrombomodulin, and plasminogen activator inhibitor-1 levels in patients with essential hypertension// Cardiovasc Drugs Ther. 1998. V.12. P. 463-467.

[12] Ruksin V.V.,Grishin O.V.,Chiritso M.M. The efficacy of antihypertension drugs and their combinations in the non-treated hypertension// Med. Tr. Prom. Ekol.2013. № 5. P.7-11.

[13] Chazova I.E., Almazov V.A., Shlyakhto E.V. Moxonidine improves glycaemic control in mildy hypertensive, overweight patients: a comparison with metformin // Diabetes, Obesity and Metabolism. 2006. V.8. P.456-465.

[14] Chazova I, Schlaich M.P. Improved hypertension control with the imidazoline agonist moxonidine in a multinational metabolic syndrome population: principal results of the MERSY Study // International J. Hypertension. 2013. № 1. P. 1-9.

[15] Sharma A.M., et al.Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study// J. Hum. Hypertens. 2004. V. 18. P. 669-675.

[16] Holecki M., Dulawa J., Chulek J. Resistant hypertension in visceral obesity// Eur. J. Intern. Med. 2012. V. 23. P. 643-648.

[17] Bramalage P., Pittrow D., Witchen H.U.,et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly contolled // Am. J. Hyperens. 2004. V.17. P. 904-910.

[18] Jordan J., Yumuk V., Schlaich M., et al. Joint statement of the European Association for the study of the study of obesity and the European Society of Hypertension obesity and difficult to treat arerial hypertension // J. hypertens. 2012. V. 30 P. 1047-1055.

[19] Engbaek M., Hjerrild M., Hallas J., Jacobsen I.A. The effect of low-dose spironolactone on resistant hypertension // J. Am. Soc. hypertens. 2010. V.4. P.290-294.

[20] Tsioufis C., Kordalis A., Flessas D. et al. Pathophysiology of resistant hypertension: the role of sympathic nervous system // Int. J. Hypertens. 2011. № 2. P. 34-41.

[21] SagaradS.V., Biradar-Kerure S., Ramakrishna M.R., Chaitanya K.S, Reddy S.S. A Prospective Real World Experience of Moxonidine Use in Indian Hypertensive Patients-Prescription beyond Current Guidelines// J. Clin. Diagn. Res. 2013. V. 7(10). P. 2213-2215.

[22] Bousquet P., Feldman. J, Schwartz J. Central cardiovascular effects of alpha-adrenergic drugs: difference between catecholamines and Imidazolines // J. Pharmacol. Exp. Ther. 1984. V. 230. P.232-236.

[23] Подзолков В.И., Можарова Л.Г., Хомицкая Ю.В.Применение моксонидина для коррекции артериальной гипертонии у женщин с климактерическим синдромом // Кардиоваскулярная терапия и профилактика. 2005. №5. C. 83-88.

[24] Cohn J.N., Pfeffer M.A., Rouleauc J., et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON) // Eur. J. Heart Fail. 2003. № 5. P. 659-667.

Аннотация

Для цитирования

Похожие статьи